Increased expression of Toll-like receptors (TLRs) 7 and 9 and other cytokines in systemic lupus erythematosus (SLE) patients: Ethnic differences and potential new targets for therapeutic drugs

Molecular Immunology

Volumn 61, Issue 1, 2014, Pages 38-43

  Lyn Cook, Beverly D ^c   Xie, Chenghui ^c   Oates, Jarren ^a   Treadwell, Edward ^b   Word, Beverly ^c   Hammons, George ^b   Wiley, Kenneth ^b  

^a UNIVERSITY OF ARKANSAS AT PINE BLUFF   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

^c NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

African American women; Interferon gamma; Interleukin 6; Systemic lupus erythematous; Toll like receptors; Tumor necrosis factor alpha

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICAN; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; HUMAN; HUMAN CELL; INNATE IMMUNITY; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

AFRICAN AMERICAN WOMEN; INTERFERON GAMMA; INTERLEUKIN-6; SYSTEMIC LUPUS ERYTHEMATOUS; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR ALPHA;

AFRICAN AMERICANS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901372510     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.05.001     Document Type: Article

References (31)

1. Akira S., Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004, 4:499-511.
2. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
3. Anders H.-J. A toll for lupus. Lupus 2005, 14(6):417-422.
4. Barrat F.J., Meeker T., Chan J.H., Guiducci C., Coffmann R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007, 37(12):3582-3586.
5. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300(5625):1524-1525.
6. Christensen S.R., Shlomchik M.J. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin. Immunol. 2007, 19(1):11-23.
7. Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 2005, 202(2):321-331.
8. Graham R.R., Kyogoku C., Sigurdsson S. Three functional variants of IFN regulatory factor 5 define risk and protective haplotypes for human lupus. PNAS 2007, 104(16):6758-6763.
9. Harley I.T.W., Kaufman K.M., Langefeld J.B., Kelly J.A. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. Nat. Rev. Genet. 2009, 10(265):680-688.
10. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
11. Horton C.G., Pan Z., Farris A.D. Targeting Toll-like receptors for treatment of SLE. Mediat. Inflamm. 2010, 498980:1-13.
12. Huang Q., Pope R.M. Toll-like receptor signaling: a potential link among rheumatoid arthritis, systemic lupus, and atherosclerosis. J. Leukoc. Biol. 2010, 88:253-262.
13. Iwasaki A., Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 2010, 327:291-295.
14. Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007, 19(1):24-32.
15. Kawai T., Akira S. Toll-like receptor and RIG-1-like receptor signaling. Ann. N. Y. Acad. Sci. 2008, 1143:1-20.
16. Kono D.H., Haraldsson M.K., Lawson B.R., et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(29):12061-12066.
17. Lafyatis R., Marshak-Rothstein A. Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res. Ther. 2007, 9(6):222.
18. Marshak-Rothestein A. A Toll-like receptor in systemic autoimmune diseases. Nat. Rev. Immunol. 2006, 6:823-835.
19. Moser K.L., Kelly J.A., Lessard C.J., Harley J.B. Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun. 2009, 10(5):373-379.
20. O'Neill L.A.J., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signaling. Nat. Rev. Immunol. 2007, 7(5):353-364.
21. Park Y., Park S., Yoo E., Kim D., Shin H. Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann. N. Y. Acad. Sci. 2004, 1037:170-174.
22. Pradhan V.D., Das S., Surve P., Ghosh K. Toll-like receptors in autoimmunity with special reference to systemic lupus erythematosus. Indian J. Hum. Genet. 2012, 18(2):155-160.
23. Roelofs M.K., Wenink M.H., Brentano F., et al. Type 1 interferons might form the link between Toll-like receptor 3/7 and TLR4-mediatd synovial inflammation in rheumatoid arthritis (RA). Ann. Rheum. Dis. 2009, 68(9):1486-1493.
24. Roelofs M.F., Wenink M.H., Brentano F., et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann. Rheum. Dis. 2009, 68(9):1486-1493.
25. Ronnblom L., Eloranta M.L., Alm G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006, 54:408-420.
26. Saitoh H., Miyake K. Regulatory molecules required for nucleotide-sensing Toll-like receptors. Immunol. Rev. 2009, 227:32-43.
27. Schoenemeyer A., Barnes B.J., Mancl M.E., et al. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 2005, 280(17):17005-17012.
28. Shotorbani S.S., Su Z.-L., Xu H.-X. Toll-like receptors are potential therapeutic targets in rheumatoid arthritis. World J. Biol. Chem. 2011, 2(7):167-172.
29. Takeda K., Akira S. Toll-like receptors in innate immunity. Int. Immunol. 2005, 17(1):1-14.
30. Yamamoto M., Sato S., Hemmi H., et al. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 2003, 301(5633):640-643.
31. Yao Y., Richman L., Higgs B.W., et al. Neutralization of interferon-α/ß-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in system lupus erythematosus. Arthritis Rheum. 2009, 60(6):1785-1796.